The use of short courses of physiological or pharmacological doses of estradiol to induce apoptosis in breast cancer cells with a hypersensitive ER in women whose tumours are resistant to multiple types of endocrine therapy including AIs has been suggested based upon preclinical models (96,97). This evidence concerns the gene ESR1 and breast cancer.